Acute Coronary Syndrome News and Research

RSS

Miracor granted CE-Mark for PICSO Impulse System to improve ACS revascularization following PCI

Miracor Medical Systems GmbH announced today that the company has received CE-mark for the PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System, designed to improve acute coronary syndrome (ACS) revascularization following primary percutaneous coronary intervention (PCI).

16 Dec 2010

Sheathless transradial intervention highly successful in treating complex lesions

Cardiologists from the Mayo Clinic performed sheathless transradial percutaneous coronary intervention (PCI) to remedy complex lesions, achieving a 90% success rate with no radial complications. Standard guiding catheters were used during the procedure. Details of this novel approach—overcoming the last hurdle to greater adoption of transradial PCI in the U.S.—are published in the December issue of Catheterization and Cardiovascular Intervention, the official journal of The Society for Cardiovascular Angiography and Interventions.

7 Dec 2010

Cardiologists achieve 90% success rate in sheathless transradial PCI to remedy complex lesions

7 Dec 2010

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.

22 Nov 2010

Bristol-Myers Squibb, Pfizer discontinue Phase 3 APPRAISE-2 trial in patients with ACS

Bristol-Myers Squibb Company and Pfizer today reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with recent Acute Coronary Syndrome (ACS) treated with apixaban or placebo in addition to mono or dual antiplatelet therapy.

19 Nov 2010

TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients

New results from an observational substudy from TRITON–TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with Efient/Effient (prasugrel) prior to coronary artery bypass graft surgery (CABG) had a reduced overall mortality rate compared to patients treated with Plavix (clopidogrel)

17 Nov 2010

BioInvent receives FDA IND clearance for BI-204 Phase II trial in cardiovascular disease

BioInvent International AB today announces IND clearance from the U.S. Food & Drug Administration (FDA) to initiate a Phase II study for BI-204. BI-204 is a human monoclonal antibody that specifically targets oxidized forms of a low-density lipoprotein (LDL) which has been linked to increased inflammatory processes leading to plaque formation in the blood vessel walls. BI-204 is being co-developed with Genentech for secondary prevention of cardiovascular events in patients with acute coronary syndrome (ACS).

10 Nov 2010

Experts at XXXIII World Congress present new clinical challenges about thrombotic disorders

Pharmaceutical Strategic Initiatives announced today that some of the leading experts in the field of thrombosis and anticoagulation provided their perspective and assessment of new clinical challenges at a recent symposium held at the XXXIII World Congress of the International Society of Hematology held in Jerusalem, Israel on October 12, 2010.

30 Oct 2010

CYP2C19 gene variant can increase risk of cardiovascular events in patients treated with clopidogrel

An analysis of data from previously published studies indicates that use of the antiplatelet drug clopidogrel for patients who have common genetic variants of a certain gene and are undergoing a procedure such as coronary stent placement have an associated increased risk for major adverse cardiovascular events, particularly development of blood clots in stents, according to a study in the October 27 issue of JAMA.

27 Oct 2010

New Canadian Cardiovascular Society guidelines support clinicians in practicing evidence-based medicine

Summaries of a number of new Canadian Cardiovascular Society guidelines and position statements offering the most up to date information to support clinicians in practicing evidence-based medicine were released at the Canadian Cardiovascular Congress 2010 this week.

25 Oct 2010

Cerenis raises €10 million in second close of Series C financing

Cerenis Therapeutics, a biopharmaceutical company specializing in the research and development of novel therapies based on HDL to treat cardiovascular and other metabolic diseases, announced today it has raised a further €10 million in a second close of its Series C financing. This takes the total funds raised in the Series C to €50 million and the total equity investment raised to date by the Company to €117 million.

21 Oct 2010

Clinical trial results of Genous Bio-engineered R stent, EPC capture technology presented at TCT 2010

OrbusNeich today announced that clinical trial results highlighting the company's Genous Bio-engineered R stent and its endothelial progenitor cell capture technology across challenging patient subsets were presented during a symposium titled "EPC Capture Technology: from Genous to Combo" at Transcatheter Cardiovascular Therapeutics 2010 in Washington.

27 Sep 2010

Erasmus Medical Center Professor to present LEADERS trial result at TCT symposium

Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer. The results will be presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

23 Sep 2010

Celera receives patent on KIF6 gene variant

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,799,530 relating to methods of determining heart attack risk by detecting the KIF6 gene variant and reduction of such increased risk by statin therapy.

21 Sep 2010

Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation

A study evaluating the level of platelet aggregation achieved after switching from Plavix (clopidogrel) 75 mg once-daily maintenance dosing plus aspirin to Effient(prasugrel) 10 mg once-daily maintenance dosing (MD) in patients with acute coronary syndrome (ACS) was published today in the Journal of the American College of Cardiology.

14 Sep 2010

Ticagrelor exhibits potential for prevention of heart attacks

New findings from a major drug trial have brought experts a step closer to developing a drug which could prevent thousands of British deaths from heart attacks.

13 Sep 2010

Resverlogix announces key changes to Phase 2 ASSURE trial

Resverlogix Corp. announces that the Company's Phase 2 clinical trial, called ASSURE (ApoA-1 Synthesis Stimulation in Acute Coronary Syndrome patients), has made important modifications to the design of the trial which have the potential to demonstrate a more powerful endpoint for the planning of future clinical trials for RVX-208.

10 Sep 2010

Late breaking clinical trials in interventional cardiovascular medicine to be presented at TCT 2010

Clinical trials in a variety of areas within interventional cardiovascular medicine that will be presented at TCT 2010 will directly affect the way that people with cardiovascular disease are treated. Breakthroughs in science and medical research, presented exclusively at TCT, will lead to new treatments that are minimally invasive and involve shorter recovery times. Among the topics being covered are stenting in the femoral artery, polymer-free drug-eluting stents, valves and drug-eluting balloons used in angioplasty.

8 Sep 2010

Data from ESC confirms reduction in adverse events with CYPHER Stent

Additional Analysis of 18 Month Data of the SORT OUT III Trial Provides Detail on Safety and Efficacy Outcomes in Patients With Diabetes, Acute Coronary Syndrome, or Treatment of Multiple Lesions

3 Sep 2010

Iroko Cardio International Sàrl announces data on HDB dosing of tirofiban, abciximab in interventional cardiology

Iroko Cardio International Sàrl announces long-term, three-year, mortality data from the Phase III, open label, multi-national study comparing high-dose bolus (HDB) dosing of AGGRASTAT(tirofiban) (25mcg/kg bolus followed by a 0.15mcg/kg/min infusion for 18-24 hours) vs. ReoPro (abciximab) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), presented at the 2010 European Society of Cardiology Meeting in Stockholm, Sweden.